The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it ...

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

UnitedHealth Group Incorporated (NYSE ... along with Cigna’s Express Scripts and CVS Caremark Rx, were able to collectively pocket $7.3 billion in added revenue above cost during the five ...

Jan. 16 at 1:45 p.m. ETUnitedHealth Group's Optum Rx unit made a commitment to pass through 100% of rebates negotiated with ...